Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anthera Pharmaceuticals Inc
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Anthera Pharmaceuticals Inc since year 2005.
Table 2 shows the detailed insider transactions of Anthera Pharmaceuticals Inc since 2005.
The reporting company's ticker symbol is ANTH. The reporting company's CIK number is 1316175.
The total value of stock buying since 2005 is $6,011,494.
The total value of stock sales since 2005 is $24,150,557.
The total value of stock option exercises since 2005 is $492,027.
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2017-09 | 13,550 | $17,986 | 0 | $0 | 10,400 | $14,892 |
| 2016-09 | 0 | $0 | 0 | $0 | 5,008 | $10,416 |
| 2015-12 | 0 | $0 | 0 | $0 | 10,000 | $28,900 |
| 2015-11 | 0 | $0 | 17,500 | $93,237 | 12,500 | $20,125 |
| 2015-10 | 0 | $0 | 1,205 | $7,410 | 0 | $0 |
| 2014-06 | 0 | $0 | 0 | $0 | 2,000 | $4,160 |
| 2013-06 | 100,000 | $53,000 | 0 | $0 | 0 | $0 |
| 2013-05 | 10,000 | $5,900 | 0 | $0 | 0 | $0 |
| 2013-01 | 7,462,000 | $4,903,776 | 0 | $0 | 0 | $0 |
| 2012-06 | 220,000 | $165,000 | 1,283,300 | $941,942 | 0 | $0 |
| 2012-03 | 0 | $0 | 1,550,500 | $3,849,993 | 0 | $0 |
| 2012-02 | 0 | $0 | 62,000 | $493,839 | 40,000 | $10,400 |
| 2012-01 | 0 | $0 | 17,000 | $114,255 | 32,000 | $55,480 |
| 2011-12 | 0 | $0 | 221,200 | $1,418,370 | 0 | $0 |
| 2011-11 | 0 | $0 | 172,000 | $1,181,380 | 15,000 | $3,900 |
| 2011-10 | 0 | $0 | 34,617 | $220,157 | 0 | $0 |
| 2011-08 | 0 | $0 | 19,600 | $138,438 | 60,000 | $26,400 |
| 2011-07 | 0 | $0 | 15,000 | $119,250 | 34,563 | $49,814 |
| 2011-06 | 0 | $0 | 120,099 | $979,150 | 30,000 | $19,100 |
| 2011-05 | 0 | $0 | 1,929,251 | $14,593,136 | 0 | $0 |
| 2011-04 | 0 | $0 | 0 | $0 | 33,311 | $12,799 |
| 2011-01 | 0 | $0 | 0 | $0 | 11,558 | $16,470 |
| 2010-09 | 275,900 | $856,292 | 0 | $0 | 19,063 | $10,430 |
| 2010-08 | 500 | $2,400 | 0 | $0 | 0 | $0 |
| 2010-04 | 0 | $0 | 0 | $0 | 64,251 | $45,669 |
| 2010-03 | 1,000 | $7,140 | 0 | $0 | 129,895 | $163,072 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-09-20 | Thompson John Craig (President & CEO) | Buy | 8,550 | 1.32 | 11,286 |
| 2017-09-07 | Thompson John Craig (President & CEO) | Option Ex | 10,400 | 1.43 | 14,892 |
| 2017-09-07 | Truex Paul F | Buy | 5,000 | 1.34 | 6,700 |
| 2016-09-20 | Truex Paul F (Chief Executive Officer) | Option Ex | 5,008 | 2.08 | 10,416 |
| 2015-12-23 | Mueller Brian | Option Ex | 10,000 | 2.89 | 28,900 |
| 2015-11-13 | Hislop Colin (Chief Medical Officer) | Sale | 12,500 | 5.31 | 66,337 |
| 2015-11-13 | Hislop Colin (Chief Medical Officer) | Option Ex | 12,500 | 1.61 | 20,125 |
| 2015-11-11 | Hislop Colin (Chief Medical Officer) | Sale | 5,000 | 5.38 | 26,900 |
| 2015-10-12 | Odink Debra (Chief Technology Officer) | Sale | 1,205 | 6.15 | 7,410 |
| 2014-06-30 | Truex Paul F (President and CEO) | Option Ex | 2,000 | 2.08 | 4,160 |
| 2013-06-24 | Thompson David E. | Buy | 100,000 | .53 | 53,000 |
| 2013-05-31 | Dziurzynski Bogdan | Buy | 10,000 | .59 | 5,900 |
| 2013-01-30 | Isaly Samuel D | Buy | 5,700,000 | .66 | 3,762,000 |
| 2013-01-25 | Isaly Samuel D | Buy | 1,762,000 | .65 | 1,141,776 |
| 2012-06-29 | Henney Christopher S (Director) | Buy | 200,000 | .75 | 149,800 |
| 2012-06-29 | Truex Paul F (President and CEO) | Buy | 20,000 | .76 | 15,200 |
| 2012-06-29 | Isaly Samuel D | Sale | 1,283,300 | .73 | 941,942 |
| 2012-03-22 | Isaly Samuel D | Sale | 1,306,700 | 2.40 | 3,140,000 |
| 2012-03-21 | Isaly Samuel D | Sale | 125,000 | 2.87 | 358,250 |
| 2012-03-20 | Isaly Samuel D | Sale | 116,800 | 2.90 | 338,603 |
| 2012-03-01 | Odink Debra (Chief Technology Officer) | Sale | 2,000 | 6.57 | 13,140 |
| 2012-02-23 | Hislop Colin (Chief Medical Officer) | Option Ex | 40,000 | .26 | 10,400 |
| 2012-02-15 | Truex Paul F (President and C.E.O.) | Sale | 15,000 | 7.84 | 117,600 |
| 2012-02-03 | Hislop Colin (Chief Medical Officer) | Sale | 30,000 | 8.20 | 245,999 |
| 2012-02-01 | Lowe Christopher P. (C.F.O. and C.B.O.) | Sale | 15,000 | 7.66 | 114,900 |
| 2012-02-01 | Odink Debra (Chief Technology Officer) | Sale | 2,000 | 7.67 | 15,340 |
| 2012-01-31 | Truex Paul F (President and C.E.O.) | Option Ex | 20,000 | .26 | 5,200 |
| 2012-01-28 | Healy James (Director) | Option Ex | 12,000 | 4.19 | 50,280 |
| 2012-01-17 | Truex Paul F (President and Chief Executive) | Sale | 15,000 | 6.75 | 101,250 |
| 2012-01-10 | Odink Debra (Chief Technology Officer) | Sale | 800 | 6.51 | 5,205 |
| 2012-01-06 | Odink Debra (Chief Technology Officer) | Sale | 1,200 | 6.50 | 7,800 |
| 2011-12-30 | Buatois Eric (10% Owner) | Sale | 25,000 | 6.22 | 155,625 |
| 2011-12-30 | Healy James (Director) | Sale | 25,000 | 6.22 | 155,625 |
| 2011-12-22 | Buatois Eric (10% Owner) | Sale | 25,000 | 6.22 | 155,600 |
| 2011-12-22 | Healy James (Director) | Sale | 25,000 | 6.22 | 155,600 |
| 2011-12-21 | Buatois Eric (10% Owner) | Sale | 25,000 | 6.51 | 162,775 |
| 2011-12-21 | Healy James (Director) | Sale | 25,000 | 6.51 | 162,775 |
| 2011-12-15 | Truex Paul F (President and CEO) | Sale | 15,000 | 6.34 | 95,070 |
| 2011-12-13 | Isaly Samuel D | Sale | 16,200 | 6.50 | 105,300 |
| 2011-12-09 | Isaly Samuel D | Sale | 40,000 | 6.75 | 270,000 |
| 2011-11-18 | Isaly Samuel D | Sale | 3,000 | 6.50 | 19,500 |
| 2011-11-17 | Isaly Samuel D | Sale | 24,000 | 6.67 | 160,080 |
| 2011-11-16 | Isaly Samuel D | Sale | 25,000 | 6.87 | 171,750 |
| 2011-11-15 | Truex Paul F (President and CEO) | Sale | 30,000 | 6.96 | 208,710 |
| 2011-11-15 | Isaly Samuel D | Sale | 50,000 | 6.93 | 346,500 |
| 2011-11-14 | Isaly Samuel D | Sale | 5,000 | 6.95 | 34,750 |
| 2011-11-11 | Isaly Samuel D | Sale | 5,000 | 7.14 | 35,700 |
| 2011-11-08 | Hislop Colin (Chief Medical Officer) | Sale | 15,000 | 6.74 | 101,160 |
| 2011-11-08 | Hislop Colin (Chief Medical Officer) | Option Ex | 15,000 | .26 | 3,900 |
| 2011-11-03 | Lowe Christopher P. (Chief Financial Officer & CBO) | Sale | 15,000 | 6.88 | 103,230 |
| 2011-10-25 | Lowe Christopher P. (Chief Financial Officer & CBO) | Sale | 4,637 | 7.07 | 32,783 |
| 2011-10-21 | Truex Paul F (President and CEO) | Sale | 23,235 | 6.25 | 145,218 |
| 2011-10-18 | Truex Paul F (President and CEO) | Sale | 6,745 | 6.25 | 42,156 |
| 2011-08-08 | Lowe Christopher P. (Chief Financial Officer & CBO) | Option Ex | 10,000 | 1.34 | 13,400 |
| 2011-08-08 | Truex Paul F (President and CEO) | Option Ex | 50,000 | .26 | 13,000 |
| 2011-08-03 | Lowe Christopher P. (Chief Financial Officer & CBO) | Sale | 14,600 | 6.88 | 100,433 |
| 2011-08-02 | Lowe Christopher P. (Chief Financial Officer & CBO) | Sale | 5,000 | 7.60 | 38,005 |
| 2011-07-15 | Truex Paul F (President and CEO) | Sale | 15,000 | 7.95 | 119,250 |
| 2011-07-12 | Hislop Colin (Chief Medical Officer) | Option Ex | 15,000 | .26 | 3,900 |
| 2011-07-07 | Salzman Alan E | Option Ex | 19,563 | 2.35 | 45,914 |
| 2011-06-29 | Hislop Colin (Chief Medical Officer) | Option Ex | 10,000 | .26 | 2,600 |
| 2011-06-21 | Lowe Christopher P. (Chief Financial Officer & CBO) | Option Ex | 20,000 | .82 | 16,500 |
| 2011-06-16 | Salzman Alan E | Sale | 3,100 | 8.67 | 26,877 |
| 2011-06-15 | Truex Paul F (President and CEO) | Sale | 15,000 | 8.30 | 124,545 |
| 2011-06-14 | Salzman Alan E | Sale | 699 | 8.81 | 6,158 |
| 2011-06-13 | Salzman Alan E | Sale | 1,300 | 8.80 | 11,440 |
| 2011-06-10 | Isaly Samuel D | Sale | 30,000 | 8.18 | 245,400 |
| 2011-06-09 | Isaly Samuel D | Sale | 37,000 | 8.11 | 300,070 |
| 2011-06-08 | Isaly Samuel D | Sale | 33,000 | 8.02 | 264,660 |
| 2011-05-26 | Salzman Alan E | Sale | 4,800 | 8.60 | 41,280 |
| 2011-05-26 | Isaly Samuel D | Sale | 34,200 | 8.53 | 291,726 |
| 2011-05-25 | Salzman Alan E | Sale | 32,750 | 8.67 | 283,942 |
| 2011-05-25 | Isaly Samuel D | Sale | 4,800 | 8.65 | 41,520 |
| 2011-05-24 | Salzman Alan E | Sale | 52,196 | 8.42 | 439,490 |
| 2011-05-23 | Salzman Alan E | Sale | 26,703 | 8.18 | 218,430 |
| 2011-05-19 | Salzman Alan E | Sale | 125,000 | 8.03 | 1,003,749 |
| 2011-05-18 | Isaly Samuel D | Sale | 138,668 | 8.03 | 1,113,504 |
| 2011-05-17 | Salzman Alan E | Sale | 13,900 | 8.29 | 115,230 |
| 2011-05-17 | Isaly Samuel D | Sale | 200,000 | 8.32 | 1,664,000 |
| 2011-05-16 | Truex Paul F (President and CEO) | Sale | 15,000 | 7.16 | 107,340 |
| 2011-05-16 | Isaly Samuel D | Sale | 24,000 | 7.20 | 172,800 |
| 2011-05-11 | Isaly Samuel D | Sale | 26,000 | 7.22 | 187,720 |
| 2011-05-10 | Isaly Samuel D | Sale | 212,800 | 7.23 | 1,538,544 |
| 2011-05-09 | Isaly Samuel D | Sale | 20,000 | 7.26 | 145,200 |
| 2011-05-05 | Salzman Alan E | Sale | 387,700 | 7.01 | 2,717,777 |
| 2011-05-04 | Salzman Alan E | Sale | 200,000 | 7.00 | 1,400,000 |
| 2011-05-03 | Salzman Alan E | Sale | 100,000 | 7.00 | 700,000 |
| 2011-04-13 | Odink Debra (VP, Pharmaceutical R&D) | Option Ex | 3,311 | 1.51 | 4,999 |
| 2011-04-13 | Truex Paul F (President and CEO) | Option Ex | 30,000 | .26 | 7,800 |
| 2011-01-03 | Thompson David E. (Director) | Option Ex | 11,558 | 1.43 | 16,470 |
| 2010-09-30 | Isaly Samuel D | Buy | 19,900 | 4.08 | 81,192 |
| 2010-09-24 | Leheny A. Rachel (Director) | Buy | 250,000 | 3.00 | 750,000 |
| 2010-09-24 | Lowe Christopher P. (CFO & VP of Administration) | Buy | 5,000 | 4.18 | 20,900 |
| 2010-09-24 | Odink Debra (VP, Pharmaceutical R&D) | Buy | 1,000 | 4.20 | 4,200 |
| 2010-09-21 | Trias Joaquim (Sr. VP, Preclinical Developmen) | Option Ex | 4,380 | 1.51 | 6,613 |
| 2010-09-21 | Hislop Colin (Sr. VP, Cardiovasc. Prod.) | Option Ex | 14,683 | .26 | 3,817 |
| 2010-08-18 | Hislop Colin (Sr. VP, Cardiovasc. Prod.) | Buy | 500 | 4.80 | 2,400 |
| 2010-04-07 | Truex Paul F (President and CEO) | Option Ex | 23,364 | .14 | 3,270 |
| 2010-04-01 | Henney Christopher S (Director) | Option Ex | 40,887 | 1.04 | 42,399 |
| 2010-03-31 | Lowe Christopher P. (CFO & VP of Administration) | Option Ex | 9,637 | .20 | 1,927 |
| 2010-03-04 | Leheny A. Rachel (Director) | Option Ex | 120,258 | 1.34 | 161,145 |
| 2010-03-01 | Truex Paul F (President and CEO) | Buy | 1,000 | 7.14 | 7,140 |
Insider trading activities including stock purchases, stock sales, and option exercises of ANTH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Anthera Pharmaceuticals Inc (symbol ANTH, CIK number 1316175) see the Securities and Exchange Commission (SEC) website.